Trial results

Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease

NCT03439943 on ClinicalTrials.gov · last registry update 2025-11-28

Finished 15 April 2021, after enrolling 156 people. lixisenatide is approved in the US, but not for neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P2

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

University Hospital, Toulouse

Sponsor type

Other

Enrollment

156

Started

2018-06-13

Primary completion

2021-04-15 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Change from baseline to end-point (M12) in the MDS-UPDRS III motor (Movement Disorder Society-Unified Parkinson's disease rating scale)

Conditions studied

Parkinson Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.